Pioglitazone Use in Combination with Insulin in the Prospective Pioglitazone Clinical Trial in Macrovascular Events Study (PROactive19)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pioglitazone Use in Combination with Insulin in the Prospective Pioglitazone Clinical Trial in Macrovascular Events Study (PROactive19)

Published:2010-05-01 Issue:5 Volume:95 Page:2163-2171
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Charbonnel Bernard¹,DeFronzo Ralph²,Davidson Jaime³,Schmitz Ole⁴,Birkeland Kare⁵,Pirags Valdis⁶,Scheen André⁷,

Affiliation:

1. Clinique d’Endocrinologie, Maladies Metaboliques, et Nutrition (B.C.), 44093 Nantes, France

2. Diabetes Division (R.D.), The University of Texas Health Science Center, San Antonio, Texas 78229

3. Medical City Hospital (J.D.), Dallas, Texas 75230

4. Department of Medicine M (Endocrinology and Diabetes) (O.S.), Århus Kommunehospitalet, DK-8000 Aarhus, Denmark

5. Department of Clinical Endocrinology (K.B.), Aker University Hospital, 0514 Oslo, Norway

6. Department of Internal Medicine (V.P.), Paula Stradina Kliniska Universitates Slimnica, 1002 Riga, Latvia

7. Division of Diabetes, Nutrition, and Metabolic Disorders (A.S.), Department of Medicine, University of Liège, 4000 Liège, Belgium

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/95/5/2163/9067560/jcem2163.pdf

Reference25 articles.

1. The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of type 2 diabetes;Kahn;Diabetologia,2003

2. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease;U.K. Prospective Diabetes Study Group;Diabetes,1995

3. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes;Charbonnel;Diabetología,2005

4. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes;Hanefeld;Diabetes Care,2004

5. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy;Kahn;N Engl J Med,2006

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial;Diabetes, Obesity and Metabolism;2021-10-07

2. Efficacy and Cardiovascular Safety of Thiazolidinediones;Current Drug Safety;2021-06-08

3. Pleural Effusion Due to Use of Pioglitazone: A Case Report;Metabolic Syndrome and Related Disorders;2020-04-01

4. Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction;Journal of Cardiac Failure;2019-12

5. RSSDI consensus recommendations on insulin therapy in the management of diabetes;International Journal of Diabetes in Developing Countries;2019-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3